Harvard Apparatus Regenerative Technology, Inc. (HRGN) is a bioengineering company founded in 2012. Their slogan, "HRGN is a bioengineering company that is developing next-generation esophageal implants." succinctly captures their mission. The company is based in the United States and operates within the Biotechnology and Health Care sectors. Their focus is on developing organ replacement therapies using cellular scaffolds and tissue engineering to restore organ function. The most recent investment in HRGN was a $6.00M Post-IPO Equity investment on 31 March 2023. This investment indicates continued confidence in the company's innovative approach to regenerative medicine. As the company progresses through its clinical stage, the level of interest from investors may further amplify, positioning HRGN for impactful growth and advancements in the field of regenerative medicine.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Post-IPO Equity | $1.50M | - | 15 Apr 2024 | |
Post-IPO Equity | $6.00M | - | 31 Mar 2023 | |
Post-IPO Equity | $5.10M | - | 13 May 2022 | |
Post-IPO Equity | $2.60M | - | 08 Sep 2021 | |
Post-IPO Equity | $500.00K | - | 18 Aug 2020 |
No recent news or press coverage available for Harvard Apparatus Regenerative Technology, Inc..